News
KDNY
40.39
0.00%
0.00
Weekly Report: what happened at KDNY last week (0226-0301)?
Weekly Report · 03/04 09:16
Weekly Report: what happened at KDNY last week (0219-0223)?
Weekly Report · 02/26 09:18
Weekly Report: what happened at KDNY last week (0212-0216)?
Weekly Report · 02/19 09:18
Weekly Report: what happened at KDNY last week (0205-0209)?
Weekly Report · 02/12 09:17
Weekly Report: what happened at KDNY last week (0129-0202)?
Weekly Report · 02/05 09:18
Weekly Report: what happened at KDNY last week (0122-0126)?
Weekly Report · 01/29 09:17
Weekly Report: what happened at KDNY last week (0115-0119)?
Weekly Report · 01/22 09:17
Weekly Report: what happened at KDNY last week (0108-0112)?
Weekly Report · 01/15 09:17
Weekly Report: what happened at KDNY last week (0101-0105)?
Weekly Report · 01/08 09:18
Weekly Report: what happened at KDNY last week (1225-1229)?
Weekly Report · 01/01 09:16
Weekly Report: what happened at KDNY last week (1218-1222)?
Weekly Report · 12/25/2023 09:18
Weekly Report: what happened at KDNY last week (1211-1215)?
Weekly Report · 12/18/2023 09:19
Weekly Report: what happened at KDNY last week (1204-1208)?
Weekly Report · 12/11/2023 09:19
Weekly Report: what happened at KDNY last week (1127-1201)?
Weekly Report · 12/04/2023 09:18
Weekly Report: what happened at KDNY last week (1120-1124)?
Weekly Report · 11/27/2023 09:17
Weekly Report: what happened at KDNY last week (1113-1117)?
Weekly Report · 11/20/2023 09:17
Weekly Report: what happened at KDNY last week (1106-1110)?
Weekly Report · 11/13/2023 09:16
Weekly Report: what happened at KDNY last week (1030-1103)?
Weekly Report · 11/06/2023 09:16
Weekly Report: what happened at KDNY last week (1023-1027)?
Weekly Report · 10/30/2023 09:19
Weekly Report: what happened at KDNY last week (1016-1020)?
Weekly Report · 10/23/2023 09:18
More
Webull provides a variety of real-time KDNY stock news. You can receive the latest news about Chinook Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KDNY
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.